Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03459079
Recruitment Status : Recruiting
First Posted : March 8, 2018
Last Update Posted : March 23, 2021
Inventiva Pharma
Information provided by (Responsible Party):
University of Florida

Brief Summary:
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Specifically, to determine if lanifibranor decreases intrahepatic triglycerides (IHTG) (primary endpoint), improves hepatic insulin sensitivity, endogenous (hepatic) glucose production, de novo lipogenesis (DNL), HbA1c and lipid profiles. In addition, exploratory analysis with surrogate plasma biomarkers and imaging on liver fibrosis changes on with treatment will be performed.

Condition or disease Intervention/treatment Phase
Nonalcoholic Fatty Liver Disease (NAFLD) Type 2 Diabetes (T2DM) Drug: Lanifibranor Other: Placebo Phase 2

Detailed Description:

The study is a two-arm (placebo, lanifibranor 800 mg/day), randomized (1:1), double-blind, placebo-controlled, 24-week treatment study. Thirty four (n=34)patients with T2DM will be randomized, allowing for a 10% drop-out rate. The diagnosis of NAFLD on imaging will be done by measuring IHTG using the gold-standard magnetic resonance and spectroscopy (¹H-MRS) technique. Ten non-diabetic subjects without NAFLD will also serve as a control group for the metabolic and imaging procedures. The study will last 34-36 weeks (~6-8 weeks for run-in, 24 weeks of treatment and 4 weeks post-study follow-up), with an estimated recruitment period of ~9 months. Patients with uncontrolled T2DM and a diagnosis of "fatty liver" per history (elevated AST/ALT and/or liver fat on liver ultrasound or ¹H-MRS and/or other appropriate imaging technique - see below). Participants may be treated by diet only, or be on a stable dose of metformin and/or a sulfonylurea and/or a DPP-IV inhibitor for ≥ 2 months prior to enrollment. If the HbA1c is ≤8.0% on any of these diabetes medications, the dose of these medications will be kept stable throughout the study and baseline studies performed as outlined below. If the HbA1c is > 8.0% but ≤ 9.5%, metformin (minimum dose required: 1,000 mg/day for metformin) and/or a sulfonylurea (minimum dose required: glimepiride 2 mg once daily) will be added, or doses maximized, during the first 2 weeks of the lead-in period. Afterwards, patient's metformin or sulfonylurea dose will be maintained at the new dose stable for 4 weeks before baseline metabolic and study-specific liver imaging.

After patients sign the informed consent and meet eligibility criteria, baseline imaging and metabolic studies will be performed. These will include measurement of IHTG by 1H-MRS, liver fibrosis by VCTE (Fibroscan) and MRE, and additional imaging by T1 MRI mapping. Metabolic testing will be done with the patient being admitted to the CRC (clinical research unit) for an overnight stay. Assessment of insulin sensitivity and DNL will be done with the administration of stable isotopes of glucose (intravenously) and deuterium labeled water (orally) to measure glucose and lipid turnover and substrate oxidation (with indirect calorimetry) during a euglycemic hyperinsulinemic clamp.

After all baseline tests are completed, patients will be asked to take a therapeutic dose of 800 mg lanifibranor (QD), or placebo, for 24 weeks. They will be closely followed by study staff every 4 weeks with visits to the CRC and interim phone calls. At 24 weeks, all baseline tests will be repeated and treatment considered completed. There will be a final, off-drug, safety follow-up visit 4 weeks after treatment at week 28. After this the participant will have completed all study procedures.

Note: The investigators recalculated the sample size for the primary endpoint of change in intrahepatic triglyceride (IHTG) measured by 1H-MRS with lanifibranor (800 mg/day) vs. placebo based on the data from the population with diabetes from the Phase IIb NATIVE (NCT03008070: NAsh Trial to Validate IVA337 Efficacy; liver histology results) and comparing to prior studies by Dr. Cusi et al that had simultaneous liver histology and liver fat measured by 1H-MRS (Belfort et al, NEJM 2006; Cusi et al, Annals Int Med 2016). From this analysis, the required sample size per group calls for 15 patients in each arm (lanifibranor vs. placebo) to complete treatment. Conservatively assuming that 10 % of the randomized patients will not complete the trial (dropouts), the total number of patients to be randomized is 33-34 patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A two arm randomized (1:1), double-blind, placebo-controlled, trial.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: double-blind, placebo-controlled trial.
Primary Purpose: Treatment
Official Title: Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Actual Study Start Date : August 14, 2018
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Arm Intervention/treatment
Active Comparator: lanifibranor arm
Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
Drug: Lanifibranor
The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
Other Name: IVA 337

Placebo Comparator: Placebo
Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
Other: Placebo
Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.

Primary Outcome Measures :
  1. Change in intrahepatic triglycerides (IHTG) quantified by proton magnetic resonance and spectroscopy (¹H-MRS) [ Time Frame: 24 weeks of treatment ]
    Changes from baseline will be compared between both arms.

Secondary Outcome Measures :
  1. Proportion of patients with a decrease from baseline in IHTG (quantified by ¹H-MRS) to week 24 of ≥ 30%. [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  2. Proportion of patients with NAFLD resolution, defined as having ≤ 5.5% IHTG (quantified by 1H- MRS). [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  3. Improvement in hepatic insulin sensitivity and de novo lipogenesis. [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  4. Improvement in adipose tissue insulin sensitivity. [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  5. Improvement in muscle insulin sensitivity (Rd). [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  6. Change in glycemic control (HbA1c). [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  7. Change in plasma lipid profile. [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  8. Changes in hepatic fibrosis on imaging. [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

  9. Change in plasma biomarkers of liver fibrosis. [ Time Frame: 24 weeks of treatment. ]
    Changes from baseline will be compared between both arms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Be able to communicate meaningfully with the investigator and legally competent to provide written informed consent
  2. Have an age between 21 to 75 years inclusive.
  3. Have uncontrolled diabetes with a fasting plasma glucose (FPG) ≥ 100 mg/dL but ≤ 250 mg/dL and HbA1c ≥ 6.0% but ≤ 9.5%, on diet alone, or on metformin (≥1,000 mg/day), and/or sulfonylurea and/or DPP-IV therapy, SGLT2 inhibitors and/or GLP-1RA. These medicines will be continued at stable doses during the entire study.
  4. Presence of hepatic steatosis (Intrahepatic Triglycerides IHTG) ≥ 10 % determined by Nuclear Magnetic Resonance Techniques.
  5. Have no new symptoms associated with decompensated diabetes in the previous 3 months.
  6. Have been on a stable dose of allowed chronic medications for two months prior to entering the double-blind treatment period.
  7. Compensated liver disease with the following hematologic and biochemical criteria on entry into protocol:

    • Hemoglobin > 11 g/dL for females and > 12 g/dL for males
    • White blood cell (WBC) > 2.5 K/µL
    • Neutrophil count > 1.5 K/µL
    • Platelets > 100 K/µL
    • Total bilirubin ≤1.3 mg/dl (22.2 µmol/L). Patients with bilirubin ≥22.2 µmol/L can be included if non-conjugated bilirubin in the setting of a Gilbert's syndrome.
    • Albumin > 36 g/L
    • Serum creatinine < 1.3 mg/dL (males) or < 1.1 mg/dL (females) or estimated glomerular filtration rate ≥ 60 mL/min/1.73m2
  8. No other causes of chronic liver disease (autoimmune, primary biliary cholangitis, HBV, HCV, Wilson's, α-1-antitrypsin deficiency, hemochromatosis, other).
  9. Negative pregnancy test or at least two-year post-menopausal. Women with childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile) must be using a highly effective method of contraception (i.e. combined (estrogen and progesterone containing) hormonal/ progesterone-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner). The contraceptive method will have to be followed for at least one menstruation cycle after the end of the study.

Exclusion Criteria:

  1. Evidence of another form of liver disease.
  2. History of excessive alcohol intake, defined by ≥ 21 units of alcohol per week in males and ≥14 units of alcohol per week in females for two years prior to enrollment, where a "unit" of alcohol is equivalent to 12-ounce beer, 4-ounce glass of wine, or 1 ounce shot of hard liquor.
  3. Unstable metabolic condition: Weight change > 5 kg in the last three months, diabetes with poor glycemic control (HgbA1c > 9.5% or FPG > 250 mg/dl), introduction of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening.
  4. History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months.
  5. Subjects on sulfonylureas, metformin, DPP-IV, GLP-1RA, unless the dose has been stable for at least 2 months prior to study entry.
  6. Patients on insulin, pioglitazone (or prior use in the past 12 months)
  7. Patients on any of the following medications unless the patient has been on stable doses of such agents for the past two (2) months before entry into the study: thiazide or furosemide diuretics, beta- blockers, or other chronic medications with known adverse effects on glucose tolerance levels. Patients may be taking stable doses of estrogens or other hormonal replacement therapy if the patient has been on these agents for the prior two (2) months. Patients taking systemic glucocorticoids will be excluded.
  8. Patients with history of myopathies or evidence of active muscle diseases
  9. Unstable cardiovascular disease, including unstable angina (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of New York Heart Association class (III-IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months
  10. History of (within prior 3 months) or current unstable cardiac dysrhythmias
  11. Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg.
  12. Stroke or transient ischemic attack within the prior 6 months
  13. History of malignancy in the past 5 years and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer
  14. History of bladder disease and/or hematuria or has current hematuria unless due to a urinary tract infection
  15. Any of the following laboratory values:

    1. Serum bilirubin > 1.3 mg/dL (or > 22.2 µmol/L). Patients with bilirubin > 1.3 mg/dL can be included if non-conjugated bilirubin in the setting of a Gilbert's syndrome.
    2. Serum ALT > 3X ULN
    3. INR > 1.2
    4. Platelets < 150,000 per microliter of blood.
    5. Renal impairment as demonstrated by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2
    6. Total creatinine kinase > 1.5 X ULN
    7. Lipase > 1.3xULN or >2.0xULN if on a DPP-IV inhibitor or GLP-1RA.
    8. Hemoglobin A1c > 9.5%
  16. Significant systemic or major illnesses other than liver disease, including those listed in exclusion criteria #8 and pulmonary disease, organ transplantation, serious psychiatric disease, that, in the opinion of the investigator, would preclude treatment with lanifibranor and/or adequate follow up.
  17. HB antigen > 0, HCV > 0 (patients with a history of HCV infection can be included if HCV PCR is negative since more than 3 years), prior history of HIV infection.
  18. Pregnancy/lactation or inability to adhere to adequate contraception in women of child-bearing potential.
  19. Any other condition which, in the opinion of the investigator would impede competence or compliance or possibly hinder completion of the study.
  20. Body mass index (BMI) > 45 kg/m2.
  21. Type 1 diabetes and type 2 diabetic patient on insulin.
  22. Diabetic ketoacidosis.
  23. Fasting plasma triglycerides > 500 mg/dL.
  24. Hemostasis disorders or current treatment with anticoagulants.
  25. Participation in any other investigational drug study within the previous 3 months.
  26. Have a known hypersensitivity to any of the ingredients or excipients of the IMP including: Lactose monohydrate, hypromellose, sodium lauryl sulphate, sodium starch glycolate, magnesium stearate, Opadry™ II 85F18422, DSS Granular, cellulose microcrystalline, maize starch.
  27. Be possibly dependent on the Investigator (e.g., including, but not limited to, affiliated employee).
  28. Osteopenia or any other well documented bone disease. Patient without well documented osteopenia treated with vitamin D and/or calcium based supplements for preventive reasons can be included.
  29. Claustrophobia to a degree that prevents tolerance of MRI scanning procedure. Sedation is permitted at discretion of investigator.
  30. Metallic implant of any sort that prevents MRI examination including, but not limited to: aneurysm clips, metallic foreign body, vascular grafts or cardiac implants, neural stimulator, metallic contraceptive device, tattoo, body piercing that cannot be removed, cochlear implant; or any other contraindication to MRI examination..

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03459079

Layout table for location contacts
Contact: Dori Romrell 352-294-5723
Contact: Diana Barb, MD 352-294-4897

Layout table for location information
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Danielle Poulton    352-294-4895   
Sub-Investigator: Fernando Bril, MD         
Sub-Investigator: Diana Barb, MD         
Sub-Investigator: Troy Donahoo, MD         
Sub-Investigator: Julio Leey, MD         
Sponsors and Collaborators
University of Florida
Inventiva Pharma
Layout table for investigator information
Principal Investigator: Kenneth Cusi, MD University of Florida
Additional Information:

Layout table for additonal information
Responsible Party: University of Florida Identifier: NCT03459079    
Other Study ID Numbers: IRB201800838 -A
PRO00018845 AGR00010853 ( Other Identifier: University of Florida )
OCR17599 ( Other Identifier: Universiy of Florida )
First Posted: March 8, 2018    Key Record Dates
Last Update Posted: March 23, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is not a plan to make IPD available.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Digestive System Diseases